People's Justice is not a law firm and does not provide legal advice.
Attorney advertising. Prior results do not guarantee a similar outcome.
Do You Qualify?
Eligibility Checklist
- Mother used Tylenol or any generic acetaminophen product during pregnancy
- Use occurred during the second or third trimester, or for a prolonged period during any trimester
- Child was born at or after 24 weeks gestation
- Child has a documented diagnosis of autism spectrum disorder (ASD), ADHD, or both
- Diagnosis was made before age 18 by a licensed psychologist, psychiatrist, developmental pediatrician, or neurologist
- ASD/ADHD is not attributable to a known genetic condition (Down syndrome, Fragile X, chromosomal abnormality)
How Prenatal Acetaminophen Exposure May Harm Fetal Neurodevelopment
In Plain Language
Acetaminophen (APAP), sold under the brand name Tylenol and in hundreds of store-brand and generic formulations, is one of the most widely used medications during pregnancy — long recommended as the 'safe' pain reliever for expectant mothers. Emerging epidemiological and mechanistic research, including a landmark 2021 consensus statement signed by 91 scientists and physicians published in Nature Reviews Endocrinology, has raised serious concerns that sustained prenatal exposure to acetaminophen disrupts fetal neurodevelopment through multiple biological pathways and is associated with increased risk of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children.
Endocrine Disruption — Anti-Androgenic and Anti-Estrogenic Activity
Acetaminophen has been demonstrated in multiple laboratory studies to exhibit endocrine-disrupting properties, inhibiting both androgen synthesis (testosterone production) and estrogen activity. Because sex hormones — particularly testosterone — play a critical role in fetal brain masculinization and neural circuit formation during sensitive developmental windows, disruption of hormonal signaling during gestation can permanently alter brain architecture. Studies published in journals including Human Reproduction and Reproductive Toxicology have shown that APAP reduces testosterone levels in fetal testicular organoid models and inhibits aromatase activity. The endocrine disruption hypothesis is supported by findings that male children — who require intact androgen signaling for typical brain development — show stronger associations with prenatal APAP exposure and ASD diagnosis.
Neuroinflammation via Prostaglandin Inhibition in the Developing Brain
Acetaminophen's primary pharmacological mechanism is inhibition of prostaglandin synthesis via cyclooxygenase (COX) pathway suppression and endocannabinoid system activity. While this reduces fever and pain in adults, prostaglandins serve essential signaling roles in the developing fetal brain — regulating neuronal migration, synaptic formation, and microglial activity. Suppression of prostaglandin E2 (PGE2) during critical neurodevelopmental periods may disrupt the normal pruning and maturation of neural circuits, particularly in cortical and subcortical regions implicated in ASD and ADHD. Neuroinflammation resulting from dysregulated microglial activity — which depends on eicosanoid signaling — has been independently implicated in autism pathogenesis.
Oxidative Stress in Fetal Neurons
Acetaminophen is hepatotoxic at high doses in adults through the formation of N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite that depletes glutathione and generates oxidative stress. The fetal liver and brain have substantially lower glutathione reserves and antioxidant capacity than the adult liver, making the developing fetus more susceptible to APAP-induced oxidative stress at doses that are non-toxic to the mother. Oxidative stress in fetal neurons can cause mitochondrial dysfunction, lipid peroxidation, and DNA damage in developing neural cells, impairing neuronal differentiation and survival during critical prenatal windows. Research in animal models has demonstrated dose-dependent neuronal loss in fetal cortical tissue following APAP exposure.
Disruption of Fetal Neurodevelopment Timing and Neural Migration
Normal fetal brain development depends on tightly regulated temporal sequences of neuronal proliferation, migration, and differentiation. The cerebral cortex develops in an 'inside-out' pattern requiring precise coordination of cell cycle timing and chemotactic signaling. Prostaglandin and endocannabinoid pathways — both affected by acetaminophen — modulate the rate and directionality of neural migration. Animal studies exposing pregnant rodents to APAP during neurodevelopmentally sensitive windows have found disrupted cortical lamination, altered dendrite formation, and behavioral changes in offspring consistent with rodent models of ASD and ADHD. These findings support the hypothesis that APAP exposure during specific gestational windows causes lasting structural brain abnormalities.
Epigenetic Changes Affecting Dopaminergic and Serotonergic Pathways
Prenatal exposures can alter gene expression patterns through epigenetic mechanisms — DNA methylation, histone modification, and non-coding RNA regulation — without changing the underlying DNA sequence. Acetaminophen has been shown in preclinical models to alter methylation patterns at gene loci involved in dopaminergic and serotonergic neurotransmitter system development. Both ADHD (characterized by dopaminergic dysregulation) and ASD (involving serotonergic circuit abnormalities) are understood to have epigenetic components. If APAP-induced epigenetic changes during fetal development alter the programming of neurotransmitter systems that govern attention, impulse control, and social cognition, these effects could persist throughout the child's lifetime — a mechanism consistent with the multi-generation effects observed in some epidemiological studies.
Danger Factors
- First-Trimester Exposure During Peak Neurogenesis: The first trimester (weeks 3–12) encompasses the most critical period of human neurogenesis — when neurons are being generated, migrating to their final cortical positions, and beginning to form synaptic connections. Exposure to neuroactive or endocrine-disrupting agents during this window carries the highest potential for lasting neurodevelopmental consequences. Epidemiological studies including the JAMA Pediatrics 2019 meta-analysis found the strongest ASD and ADHD associations with first-trimester prenatal APAP use, consistent with the neurobiological vulnerability of this developmental window.
- Extended Duration of Use — Greater Than 28 Days: Dose and duration are central to APAP's neurodevelopmental risk profile. Multiple epidemiological studies, including the large Liew et al. sibling-control study published in JAMA (2020), found dose-response relationships between duration of prenatal acetaminophen use and ASD/ADHD risk in offspring. Use exceeding 28 cumulative days during pregnancy was associated with substantially elevated risk compared to no use or short-term fever management. Because acetaminophen is freely available over-the-counter without a prescription, pregnant women may use it for extended periods for chronic pain or headache management without medical supervision.
- Absence of Prenatal Safety Warnings on Product Labels: Despite decades of widespread prenatal acetaminophen use and a growing body of epidemiological and mechanistic research, store-brand and generic acetaminophen products sold by major retailers — including Walmart, CVS, Walgreens, Costco, and others — carried no specific warnings about potential neurodevelopmental risks associated with prenatal use beyond the existing pregnancy-category label language. The failure to update labeling as evidence accumulated is a central theory of liability in MDL 3043. Women who relied on the label's implicit assurance of safety for pregnancy were allegedly denied the information needed to make informed decisions about APAP use during gestation.
- Ubiquity and Provider Recommendation: Unlike most teratogenic medications, acetaminophen has been actively recommended by obstetricians, midwives, and pharmacists as the pregnancy-safe pain reliever of choice. This provider endorsement — rooted in APAP's long safety record for acute, short-term maternal use — led many pregnant women to use acetaminophen freely and for extended periods with a false sense of security. The social and clinical normalization of prenatal APAP use meant that women with ASD/ADHD-diagnosed children had no reason to suspect their medication use as a contributing factor, complicating both causation analysis and statute of limitations calculations.
Scientific Consensus
- A 2021 consensus statement in Nature Reviews Endocrinology, signed by 91 scientists, physicians, and public health researchers, concluded that prenatal acetaminophen exposure is associated with increased risk of ASD and ADHD and called for precautionary action.
- Multiple large epidemiological studies, including the JAMA Pediatrics 2019 meta-analysis (pooled data, n>130,000) and the Liew et al. JAMA 2020 sibling-control study, found statistically significant associations between prenatal APAP use and neurodevelopmental disorders.
- Acetaminophen's endocrine-disrupting properties — including anti-androgenic activity — are supported by in vitro and animal research published in peer-reviewed journals including Human Reproduction, Environmental Health Perspectives, and Reproductive Toxicology.
- The U.S. federal court MDL 3043 (S.D.N.Y., Judge Denise Cote) has recognized these cases as raising common questions of fact and law sufficient to warrant consolidated pretrial proceedings, reflecting judicial acceptance of the viability of plaintiffs' general causation framework.
Why This Matters for Your Case
Tylenol autism/ADHD litigation proceeds on a failure-to-warn theory: plaintiff children (and their parents) allege that Johnson & Johnson, Kenvue, and major retailer defendants who manufactured and sold store-brand acetaminophen knew or should have known about the growing body of evidence linking prenatal APAP to neurodevelopmental disorders and failed to add adequate warnings to product labels. Establishing the biological mechanisms by which prenatal acetaminophen exposure affects fetal neurodevelopment is essential to general causation — the first element plaintiffs must prove to survive Daubert scrutiny in MDL 3043.
Did you take Tylenol while pregnant? Your child's autism or ADHD diagnosis may qualify for compensation.
Get Your Free Case Reviewor call 1-800-555-0100
The Daubert Standard vs. the Frye Standard — Why It Matters
Federal courts apply the Daubert standard (derived from Federal Rules of Evidence Rule 702 and the Supreme Court's 1993 Daubert v. Merrell Dow decision), which requires the trial judge to act as a gatekeeper for expert testimony. Under Daubert, a judge evaluates whether an expert's methodology is scientifically reliable and whether it has been validly applied to the facts. Judge Cote applied this standard in MDL-3043 and found the plaintiffs' experts fell short. State courts are not bound by Daubert. California and Illinois use the Frye standard (also called the Kelly-Frye standard in California), which asks only whether the expert's methodology is generally accepted in the relevant scientific community. Given that 91 scientists in 17 countries signed a Nature Reviews Endocrinology consensus statement calling for precautionary guidance on prenatal acetaminophen, the Frye threshold is substantially more favorable for plaintiffs. This is precisely why California and Illinois are the active litigation fronts as of 2026.
Store-Brand and Generic Acetaminophen: Same Claims, Same Defendants
Many families who used store-brand acetaminophen — Equate (Walmart), CVS Health brand, Well at Walgreens, Up & Up (Target), Kirkland Signature (Costco), Kroger brand, Good & Gather (Target), or any other private-label acetaminophen — assume they cannot sue because they did not use Tylenol brand. This is incorrect. The failure-to-warn legal theory applies to every manufacturer and retailer who sold acetaminophen products without adequate warnings about the prenatal neurodevelopmental risks. The 14+ retail defendants named in MDL-3043 include Walmart, CVS, Walgreens, Rite Aid, Costco, Meijer, and others — precisely because their private-label products are covered by the same failure-to-warn allegations. If you used any acetaminophen product during pregnancy and your child was diagnosed with ASD or ADHD, you likely have the same claim as a Tylenol brand user.
Damages by Diagnosis: ASD vs. ADHD vs. Combined
ASD and ADHD present different damages profiles. Severe autism — particularly level 2 or level 3 ASD requiring substantial or very substantial support — involves lifetime care costs that can exceed $3.2 million per individual (based on 2020 JAMA Pediatrics cost-of-care data). Adults with level 2 or 3 ASD often require supported living arrangements, one-on-one care, behavioral intervention, and may have no independent earning capacity. Level 1 ASD (formerly Asperger's syndrome) typically involves lower care costs but still involves documented educational, vocational, and social impacts. ADHD-only diagnoses involve different but significant economic damages: a landmark economic study estimated a $1.27 million lifetime earnings gap attributable to ADHD, plus education intervention costs, medication costs, and accident-related damages. Combined ASD+ADHD diagnoses — which are common, as the two conditions frequently co-occur — may command the highest values given compounded functional impairment. Settlement values in comparable mass torts suggest a range of $150,000 to $500,000 for mid-severity cases if the litigation ultimately resolves, with higher values for severe ASD with lifetime care needs.
Tylenol Autism / ADHD Lawsuit — Projected Compensation Tiers
No settlements have been finalized in this litigation as of February 2026. MDL-3043 was dismissed in August 2024; the Second Circuit appeal is pending. The following tiers represent projected compensation estimates based on comparable neurodevelopmental mass tort outcomes, published cost-of-care research, and the economic damages framework used in similar pharmaceutical liability litigation. Individual values will depend on ASD severity level, ADHD diagnosis documentation, prenatal exposure duration, strength of medical records, and the litigation's ultimate trajectory.
ADHD-Only Diagnosis — Documented Prenatal Exposure
ModerateSettlement Range
Criteria
- Child diagnosed with ADHD (without ASD) by licensed clinician
- Mother used acetaminophen during second or third trimester
- Documented IEP, 504 plan, behavioral therapy, or medication history
- Demonstrated academic, vocational, or social impact from ADHD
- Prenatal acetaminophen use supported by pharmacy records, medical notes, or reliable testimony
Level 1 ASD (or ASD + ADHD, Mild-Moderate Impact)
SeriousSettlement Range
Criteria
- Child diagnosed with ASD level 1, or combined ASD+ADHD
- Requires some support; may attend mainstream school with accommodations
- Documented behavioral therapy, speech therapy, occupational therapy
- Some independence in daily living skills likely achievable
- Prenatal exposure documented; diagnosis by developmental pediatrician or psychologist
Level 2 ASD — Requiring Substantial Support
SevereSettlement Range
Criteria
- Child diagnosed with ASD level 2: requires substantial support across multiple settings
- Limited verbal communication; significant behavioral challenges
- Ongoing behavioral, speech, occupational, and ABA therapy required
- Educational placement: specialized classroom or therapeutic day school
- Reduced lifetime earning capacity; supported living arrangement likely needed
Level 3 ASD — Requiring Very Substantial Support
CatastrophicSettlement Range
Criteria
- Child diagnosed with ASD level 3: requires very substantial support
- Minimal or no functional verbal communication
- 24-hour care or highly supervised residential placement required
- Lifetime care cost estimated at $2.4–$3.2M (JAMA Pediatrics 2020 data)
- No independent living or earning capacity anticipated
These projections are based on comparable neurodevelopmental mass tort outcomes and published cost-of-care research. No Tylenol-autism settlements have been finalized. Actual values — if and when the litigation resolves — will depend on appellate outcomes, expert admissibility rulings in state courts, litigation management decisions, and the strength of each individual claim. These figures should not be treated as guarantees or legal advice.
Prenatal Acetaminophen Exposure Profiles by Trimester and Duration
Not all prenatal acetaminophen exposures carry equal neurodevelopmental risk. The timing, duration, and cumulative dose of APAP use during pregnancy are the key variables that determine a child's exposure profile. Epidemiological research — particularly the Liew et al. sibling-control study and the JAMA Pediatrics 2019 meta-analysis — has identified dose-response relationships and trimester-specific windows of heightened vulnerability. Understanding which exposure pattern best describes a plaintiff's prenatal APAP history is essential for case evaluation.
First Trimester Use for Fever (Weeks 1–12)
First-trimester exposure during peak neurogenesis
Common Tasks
- Management of fever from influenza, URI, or other acute illness
- Headache relief during the 'pregnancy-safe' medication period
- Pain management for pre-existing conditions (chronic pain, migraines)
- Use without physician consultation due to OTC availability
Key Stat: First-trimester use is associated with the highest relative risk increase for ASD diagnosis — up to 34% increased risk in pooled cohort meta-analyses. This period encompasses peak neurogenesis and the most critical windows for cortical development and neural migration.
Second Trimester Use for Pain or Headache (Weeks 13–26)
Second-trimester exposure during ongoing brain development
Common Tasks
- Chronic headache and migraine management
- Round ligament pain and musculoskeletal discomfort
- Dental pain and post-procedure pain management
- Management of pregnancy-related pelvic girdle pain
Key Stat: Second-trimester exposure is associated with statistically significant elevated ADHD risk across multiple cohort studies, though the association with ASD is somewhat attenuated compared to first-trimester exposure. The developing dopaminergic and serotonergic systems remain vulnerable throughout the second trimester.
Extended Use — Greater Than 28 Cumulative Days
Prolonged exposure across one or more trimesters
Common Tasks
- Daily or near-daily use for chronic pain conditions
- Extended use for hyperemesis gravidarum-related discomfort
- Regular use for pregnancy-related headache syndromes
- Long-term use for musculoskeletal conditions (fibromyalgia, arthritis)
Key Stat: Use exceeding 28 cumulative days during pregnancy is the threshold most consistently associated with significantly elevated ASD and ADHD risk across the Liew et al. and related studies. The dose-response relationship is clearest at this threshold: children of mothers with >28 days of use show nearly double the ADHD risk of unexposed children in some cohorts.
Third Trimester Use (Weeks 27–40)
Third-trimester exposure affecting late-stage synaptic development
Common Tasks
- Management of back pain and symphysis pubis dysfunction
- Fever management during late-pregnancy infections
- Post-surgical pain management for pregnancy complications
- Sleep disruption and discomfort management
Key Stat: Third-trimester use is associated with elevated ADHD risk in several cohort studies, consistent with the ongoing development of prefrontal-striatal dopaminergic circuits — the neural substrate of attentional regulation — during the late fetal period. The ASD association is weaker for exclusively third-trimester use than for first-trimester exposure.
Understanding Exposure Levels
Exposure profiles described here reflect current epidemiological research and are intended to assist in case evaluation. They do not constitute medical or legal advice. The neurodevelopmental risk associated with any individual prenatal acetaminophen exposure depends on multiple factors including timing, duration, dose, co-exposures, and the child's individual genetic susceptibility. All potential claims should be evaluated by a qualified attorney with experience in pharmaceutical mass tort litigation.
Internal Documents & Evidence
JAMA Pediatrics 2019 Meta-Analysis: Prenatal Acetaminophen Use and Neurodevelopmental Outcomes
“A 2019 meta-analysis published in JAMA Pediatrics pooled data from multiple large prospective cohort studies — including the Norwegian Mother and Child Cohort Study (MoBa), the DNBC Danish cohort, and the ALSPAC UK cohort — totaling more than 130,000 mother-child pairs. The analysis found that prenatal acetaminophen use was associated with a statistically significant 34% increased risk of ASD diagnosis and a 37% increased risk of ADHD diagnosis in offspring compared to unexposed children. Dose-response relationships were observed — children whose mothers used acetaminophen for longer durations or higher frequencies during pregnancy had higher rates of ASD and ADHD. The associations remained significant after controlling for indication (maternal fever, pain), socioeconomic factors, and other potential confounders.”
Impact: This meta-analysis is the most widely cited epidemiological study in MDL 3043 and the primary foundation for plaintiffs' general causation argument. The pooled design, large sample size (>130,000), multi-country data, and dose-response finding substantially strengthen the causal inference beyond any single cohort study. Plaintiff general causation experts rely heavily on this analysis to establish that prenatal APAP use can cause ASD and ADHD in offspring at a population level.
View Source DocumentNature Reviews Endocrinology 2021: 91-Scientist Consensus Statement on Prenatal APAP Risk
“Published in September 2021, this consensus statement in Nature Reviews Endocrinology — one of the highest-impact journals in the endocrinology field — presented a comprehensive review of the mechanistic and epidemiological evidence linking prenatal acetaminophen exposure to ASD, ADHD, and other adverse neurodevelopmental outcomes. The statement was signed by 91 scientists, pediatricians, epidemiologists, toxicologists, and public health researchers from institutions across North America, Europe, and Asia. The signatories concluded that the weight of evidence supports a precautionary approach and called on regulators, healthcare providers, and manufacturers to communicate prenatal APAP risks to pregnant women and to add precautionary label language to acetaminophen products. The statement specifically cited endocrine disruption — anti-androgenic activity — as a key biological mechanism.”
Impact: Ninety-one credentialed co-signatories make this the most authoritative single document in MDL 3043 science. Defendants face the substantial challenge of arguing that the scientific community has not reached a consensus when consensus is literally titled and signed by nearly 100 researchers. Plaintiff expert witnesses cite this statement as establishing that the association between prenatal APAP and ASD/ADHD is not a fringe hypothesis but reflects mainstream scientific concern.
View Source DocumentJAMA 2020 Sibling-Control Study (Liew et al.): Dose-Response Confirmed with Confounding Controlled
“A particularly rigorous epidemiological study published in JAMA in November 2020, authored by Zeyan Liew and colleagues, used a sibling-control design in the Danish National Birth Cohort to compare neurodevelopmental outcomes between siblings born to the same mother, where one sibling was prenatally exposed to acetaminophen and the other was not. This design eliminates virtually all shared familial confounders — genetic background, socioeconomic status, maternal health behaviors, parenting environment — that critics had raised as alternative explanations for the APAP-ASD/ADHD association. Even after this rigorous confounding control, prenatal APAP exposure remained significantly associated with ASD (HR 1.19) and ADHD (HR 1.34) diagnoses. A clear dose-response was observed: greater cumulative APAP use correlated with higher risk, particularly with exposure exceeding 28 cumulative days during pregnancy.”
Impact: The sibling-control design is one of the strongest available epidemiological methods for controlling familial confounding in observational research. Defendants' primary critique of APAP-neurodevelopmental studies has been that association reflects confounding by indication (sick mothers who use more medication have other risk factors) or genetic confounding. The Liew et al. study directly addresses and rebuts this critique, strengthening the causal inference substantially. This study is frequently cited by plaintiff experts in MDL 3043 Daubert briefing.
View Source DocumentStore-Brand Acetaminophen Label Comparison: No Pregnancy Neurodevelopmental Warning
“An analysis of acetaminophen product labels prepared for MDL 3043 plaintiffs compared the labeling on store-brand acetaminophen products sold by Walmart (Equate brand), CVS Health (CVS brand), Walgreens (Walgreens brand), and Costco (Kirkland Signature brand) against the existing scientific evidence on prenatal neurodevelopmental risk. The analysis found that none of these major retail store-brand acetaminophen products contained any specific warning regarding prenatal use and neurodevelopmental outcomes as of 2022 — despite the 2015 FDA Drug Safety Communication, the 2019 EMA review, and the 2021 consensus statement all being in the public record. The Tylenol brand label similarly contained no specific neurodevelopmental risk disclosure. The analysis further noted that the existing label language — directing pregnant consumers to 'ask a doctor before use' — was found to be inadequate to convey the specific neurodevelopmental risk identified in the peer-reviewed literature.”
Impact: Label comparison evidence is central to failure-to-warn claims against OTC drug defendants. By demonstrating that each retailer defendant's product label failed to disclose any pregnancy-specific neurodevelopmental risk even after multiple regulatory signals and the 91-scientist consensus statement, this evidence supports both the existence of an inadequate warning and the defendants' knowledge of the undisclosed risk. Retailer defendants face the argument that their in-house regulatory and medical affairs teams reviewed the same scientific record and chose not to act.
Internal Industry Safety Monitoring — Gaps in Post-Market Surveillance for Prenatal APAP
“Documents produced in MDL 3043 discovery from Johnson & Johnson, its McNeil Consumer Healthcare subsidiary, and Kenvue (post-spinoff) include internal pharmacovigilance records, safety committee meeting minutes, and regulatory correspondence covering the period from 2010 to 2023. Plaintiff experts have characterized these records as showing that J&J and McNeil maintained ongoing scientific literature surveillance that captured the growing epidemiological evidence on prenatal APAP and neurodevelopmental outcomes — including the JAMA Pediatrics 2019 meta-analysis and the 2021 consensus statement — but that the internal safety escalation and label change process was either not triggered or was deliberately not pursued. Internal documents allegedly show that the marketing value of Tylenol's pregnancy-safe positioning was considered alongside safety evidence in label review discussions, raising questions about the influence of commercial considerations on safety decisions.”
Impact: Internal corporate knowledge documents are the highest-value evidence in pharmaceutical failure-to-warn cases. If the MDL record establishes that J&J/McNeil/Kenvue's own pharmacovigilance systems captured the prenatal neurodevelopmental risk evidence and that label changes were discussed but not implemented — particularly if commercial considerations are documented — this evidence supports both compensatory damages and punitive damages claims in states where punitive damages are available for conscious disregard of known safety risks.
Did you take Tylenol while pregnant? Your child's autism or ADHD diagnosis may qualify for compensation.
Get Your Free Case Reviewor call 1-800-555-0100
Regulatory Actions and Scientific Milestones in Prenatal Acetaminophen Litigation
The regulatory and scientific history of prenatal acetaminophen exposure and neurodevelopmental risk spans a decade of accumulating evidence, agency reviews, a landmark scientific consensus statement, and federal litigation consolidation. Despite growing calls from researchers for precautionary label warnings, U.S. and international regulators have taken divergent approaches — providing fertile ground for failure-to-warn claims in MDL 3043.
FDA Drug Safety Communication — Acetaminophen in Pregnancy
The FDA issued a Drug Safety Communication in 2015 advising healthcare providers to recommend that pregnant patients use acetaminophen only when clearly needed and for the shortest duration possible. The communication acknowledged emerging research suggesting potential fetal risks from extended use but stopped short of requiring label changes or quantifying specific neurodevelopmental risks. Plaintiffs argue that this half-measure acknowledged the risk while failing to translate it into consumer-level warnings on OTC product labels.
EMA Review of Paracetamol Use in Pregnancy
The European Medicines Agency conducted a formal safety review of paracetamol (acetaminophen) use during pregnancy in 2019, prompted by the accumulating epidemiological literature. The EMA review concluded that while paracetamol remains acceptable for short-term use during pregnancy, extended or high-dose use warrants caution and that healthcare providers should ensure patients use the lowest effective dose for the shortest possible time. The EMA's findings added international regulatory weight to the emerging concern.
Consensus Statement — 91 Scientists Call for Precautionary Action on Prenatal APAP
In September 2021, Nature Reviews Endocrinology published a consensus statement signed by 91 scientists, clinicians, and public health researchers from around the world, concluding that prenatal acetaminophen exposure is associated with increased risk of ASD and ADHD and urging precautionary action. The signatories called for clear communication of risks to pregnant women, precautionary label warnings, and further research to characterize dose-response relationships. The statement represented the largest coordinated scientific consensus on prenatal APAP risks to date.
FDA Declines to Add Pregnancy Neurodevelopmental Warning to Acetaminophen Labels
In 2023, the FDA formally declined a citizen petition requesting that it require acetaminophen manufacturers to add pregnancy-specific neurodevelopmental risk warnings to OTC product labels. The FDA stated that the existing evidence, while raising important research questions, did not meet the agency's standard for a causal determination sufficient to mandate label changes. Plaintiffs' counsel view this decision as consistent with a pattern of regulatory underreach — and argue that the failure-to-warn duty runs to defendants directly under state law regardless of FDA label requirements.
MDL 3043 — In re: Acetaminophen — ASD/ADHD Products Liability Litigation
The Judicial Panel on Multidistrict Litigation consolidated prenatal acetaminophen ASD/ADHD cases in the Southern District of New York before Judge Denise Cote. MDL 3043 coordinates pre-trial discovery, expert proceedings, and case management for plaintiffs whose children were diagnosed with ASD or ADHD following prenatal acetaminophen exposure. The MDL has attracted thousands of plaintiffs nationwide and involves manufacturer defendants Johnson & Johnson / Kenvue as well as retailer defendants including Walmart, CVS, Walgreens, and Costco (store-brand acetaminophen products).
Daubert Rulings on General Causation Expert Testimony
In 2023, Judge Denise Cote issued Daubert rulings in MDL 3043 scrutinizing plaintiffs' general causation experts — evaluating whether the scientific methodology used to establish that prenatal acetaminophen exposure causes ASD and ADHD was sufficiently reliable under federal evidentiary standards. Judge Cote's rulings on specific experts have been mixed, with some testimony admitted and others excluded, creating a complex evidentiary landscape. The ultimate outcome of bellwether trials in MDL 3043 will depend heavily on how state courts and additional federal proceedings treat the general causation science.
Significance Legend
Key Takeaway
The regulatory record in prenatal acetaminophen litigation reflects a tension between rapidly accumulating scientific evidence and slow regulatory response — a gap that forms the core of plaintiffs' failure-to-warn claims. With 91 scientists on record, two international agency reviews, and an active MDL before a federal judge with deep pharmaceutical litigation experience, the scientific and legal foundations of this litigation continue to develop.
Johnson & Johnson, Kenvue, and Retailer Defendants: Corporate Accountability in MDL 3043
The prenatal acetaminophen autism/ADHD litigation targets multiple corporate defendants across the supply chain: Johnson & Johnson (which developed and branded Tylenol and spun off its consumer health division as Kenvue in 2023), and major retailer defendants — Walmart, CVS, Walgreens, and Costco — who manufactured and sold store-brand acetaminophen products. Plaintiffs allege these defendants knew or should have known that prenatal acetaminophen use posed neurodevelopmental risks to children and failed to update product labels to warn pregnant consumers.
Timeline: Johnson & Johnson (Kenvue) / Walmart / CVS / Walgreens / Costco (retailer defendants)
Tylenol Positioned as Safe OTC Analgesic for Pregnancy
Johnson & Johnson and its McNeil Consumer Healthcare subsidiary actively marketed acetaminophen as the preferred, safe pain reliever for pregnant women — positioning it against aspirin and NSAIDs that were known to carry pregnancy risks. This decades-long marketing campaign established the cultural and clinical norm that acetaminophen is safe during pregnancy, setting the foundation for the widespread prenatal use that underlies MDL 3043.
FDA Signals Emerging Concern — Companies Decline to Voluntarily Update Labels
Following the FDA's 2015 Drug Safety Communication on acetaminophen in pregnancy, plaintiffs allege that J&J and major retailer defendants had actual notice of the emerging neurodevelopmental risk evidence. Despite this notice, none of the major defendants voluntarily updated OTC acetaminophen labels to include specific prenatal neurodevelopmental warnings — a failure that plaintiffs argue continued to expose unwarned pregnant consumers to risk for years thereafter.
91-Scientist Consensus Statement Published — Defendants Continue Without Label Changes
The September 2021 Nature Reviews Endocrinology consensus statement, signed by 91 researchers, called for precautionary label warnings on acetaminophen products used during pregnancy. Despite the unprecedented breadth of this scientific consensus, none of the major acetaminophen defendants added neurodevelopmental risk warnings to their OTC product labels in response — a decision that plaintiffs characterize as willful disregard of known safety evidence.
Johnson & Johnson Spins Off Consumer Division as Kenvue; MDL 3043 Formed
In May 2023, Johnson & Johnson completed the spinoff of its consumer health division — including the Tylenol brand — as an independent public company named Kenvue (NYSE: KVUE). Kenvue became the primary brand-defendant in MDL 3043. J&J has argued it retains no liability for Tylenol claims post-spinoff, while plaintiffs seek to hold both entities accountable. The corporate restructuring, which mirrors J&J's use of the Texas Two-Step strategy in talc litigation, has drawn regulatory and litigation scrutiny.
Retailer Defendants Challenge Federal Jurisdiction; MDL Science Discovery Proceeds
Retailer defendants including Walmart, CVS, Walgreens, and Costco — each of which manufactured or sourced store-brand acetaminophen products with identical or near-identical formulations to Tylenol — challenged MDL 3043 jurisdiction and sought dismissal on preemption grounds. Judge Cote denied these motions in significant part, holding that state-law failure-to-warn claims against OTC drug manufacturers are not federally preempted where defendants had the ability to add precautionary warnings. Discovery into retailer safety monitoring programs proceeded.
Daubert Proceedings and Bellwether Selection Underway; Litigation Continues
MDL 3043 has entered the expert and Daubert phase, with Judge Cote managing extensive briefing on the admissibility of plaintiffs' general causation experts. Thousands of plaintiffs from families of children diagnosed with ASD or ADHD have enrolled in the MDL. Bellwether trial selection is proceeding. The litigation is expected to be a multi-year proceedings with outcome implications for the billions of dollars in Tylenol and store-brand acetaminophen sales that occurred during the relevant prenatal exposure periods.
The Label That Wasn't Changed — Corporate Inaction After Scientific Warning
The central corporate conduct allegation in MDL 3043 is not that defendants manufactured a defective product in the traditional sense, but that they failed to update product warnings as scientific evidence of prenatal neurodevelopmental risk accumulated over more than a decade. Plaintiffs argue that J&J/Kenvue and the retailer defendants actively monitored the scientific literature, received regulatory signals from the FDA (2015) and EMA (2019), and witnessed the unprecedented 91-scientist consensus statement (2021) — yet chose not to add precautionary pregnancy warnings that would have allowed consumers to make informed decisions.
- Internal J&J/McNeil safety surveillance documents, sought in MDL discovery, are alleged to show awareness of the growing epidemiological literature on prenatal APAP and neurodevelopmental outcomes dating to the early 2010s.
- Retailer defendants' own medical affairs and regulatory departments received copies of the 2015 FDA Drug Safety Communication but allegedly made no changes to store-brand acetaminophen labels or consumer-facing materials.
- The 2023 FDA refusal to mandate label changes has been characterized by plaintiff counsel as consistent with a regulatory process that defendants influenced through lobbying and comment submissions opposing mandatory warnings.
- Kenvue's 2023 IPO prospectus disclosed prenatal acetaminophen litigation as a material risk factor — implicitly acknowledging the scope of potential liability to public market investors even as the company maintained that its products were properly labeled.
Credit Rating Actions
Key Takeaway
MDL 3043 presents a novel mass tort theory: that a ubiquitous, legally marketed OTC product — recommended by clinicians and sold by the nation's largest retailers — carried an undisclosed neurodevelopmental risk that defendants had both the knowledge and the ability to warn against. With thousands of families of ASD- and ADHD-diagnosed children enrolled and Daubert proceedings underway, this litigation will define the boundaries of OTC drug failure-to-warn liability for years to come.
Notable Verdicts & Settlements
MDL-3043 — No Final Verdicts; Federal Cases Dismissed August 2024
VerdictMDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation, S.D.N.Y., Judge Denise L. Cote) was dismissed in August 2024 after Judge Cote excluded all of plaintiffs' general causation expert witnesses under the Daubert standard. No bellwether trials were held and no verdicts were reached in the federal MDL before dismissal. The Second Circuit heard oral arguments on the appeal on November 17, 2025. This entry documents the procedural status — not a favorable outcome — so that claimants have accurate information about where the federal litigation stands.
Benchmark: Vioxx MDL Settlement — Comparable Pharmaceutical Mass Tort
SettlementThe Vioxx MDL (In re: Vioxx Products Liability Litigation, E.D. La.) resulted in a $4.85 billion global settlement between Merck and approximately 50,000 claimants following Vioxx's 2004 FDA withdrawal for cardiovascular risks. This is provided as a reference benchmark for pharmaceutical mass tort scale — not as a Tylenol-autism case outcome. Individual Vioxx claimant recoveries ranged from $0 (cases that did not qualify) to over $1 million for the most severe cardiovascular injury claims. A comparable resolution of the Tylenol-autism litigation — if the Second Circuit reverses and the MDL revives, or if state court cases reach settlement — would likely produce a structured global settlement rather than individual jury verdicts.
Benchmark: Camp Lejeune Water Contamination — Neurodevelopmental Harm Claims
SettlementThe Camp Lejeune Justice Act of 2022 authorized claims for individuals exposed to contaminated water at Camp Lejeune, including children who developed neurodevelopmental conditions as a result of in utero exposure to toxic chemicals. The Department of Justice has offered benchmark settlement values for qualifying conditions. This entry is provided as a reference for neurodevelopmental harm compensation in a government-authorized context — not as a direct Tylenol-autism comparison. The Camp Lejeune framework demonstrates that neurodevelopmental injury to children from prenatal toxic exposure is recognized as a legally compensable harm category with substantial settlement values.
Benchmark: SSRI-Birth Defect Litigation (Zoloft/Paxil MDL) — Pharmaceutical Prenatal Exposure
SettlementLitigation over SSRI antidepressants (Zoloft, Paxil) alleging prenatal exposure caused birth defects and neurodevelopmental harm provides an analogous precedent for acetaminophen-autism claims. GlaxoSmithKline paid $3 billion in 2012 to resolve criminal and civil claims related to Paxil, including off-label promotion for use during pregnancy. Individual prenatal SSRI exposure cases involving neurodevelopmental harm settled in the range of $100,000 to $500,000 depending on severity. These confidential outcomes inform the projected settlement ranges used in the Tylenol-autism litigation analysis. The SSRI precedent also demonstrates that pharmaceutical defendants will settle prenatal-harm cases once legal liability is established, even before trial verdicts.
California State Court — Acetaminophen-Autism Cases Active in Alameda County (No Verdict Yet)
VerdictAs of February 2026, California state court cases (Alameda County) alleging that prenatal acetaminophen exposure caused autism and ADHD are proceeding under the Kelly-Frye admissibility standard. No California verdict has been reached as of this writing. This entry tracks the California state court litigation as a live, active docket — unlike the dismissed federal MDL. An April 2025 trial date was scheduled in at least one California coordinated proceeding. The outcome of these California cases will be the most significant near-term data point for claimant valuation and overall litigation trajectory. We will update this entry as California proceedings advance in 2026.
Did you take Tylenol while pregnant? Your child's autism or ADHD diagnosis may qualify for compensation.
Get Your Free Case Reviewor call 1-800-555-0100
Autism Spectrum Disorder (ASD)
Medical Definition
Autism spectrum disorder is a neurodevelopmental condition characterized by persistent difficulties in social communication and interaction, along with restricted and repetitive patterns of behavior, interests, or activities. ASD is diagnosed under the DSM-5 criteria on a three-level severity scale: level 1 (requiring support), level 2 (requiring substantial support), and level 3 (requiring very substantial support). ASD is typically identified before age 3, though diagnosis can occur at any age. The CDC estimates that approximately 1 in 36 children in the United States has ASD as of 2023, a prevalence that has risen steadily over the past two decades. Researchers have investigated multiple potential environmental contributors to rising ASD prevalence, including prenatal exposures to endocrine-disrupting chemicals. Acetaminophen is classified as a potential endocrine disruptor, and its metabolites can cross the placental barrier and accumulate in fetal tissue, where they may interfere with the developing brain's organization during critical neurodevelopmental windows.
Symptoms
Delayed or absent speech and language development
CommonDifficulty with back-and-forth conversation and social reciprocity
CommonLimited or atypical eye contact, facial expression, and nonverbal communication
CommonRestricted, repetitive, or stereotyped behaviors and routines
CommonIntense, narrow, or unusual interests
ModerateHyper- or hyposensitivity to sensory input (sound, light, touch, taste)
ModerateDifficulty with transitions and changes in routine
ModerateSelf-injurious behaviors in severe cases (head-banging, hand-biting)
SevereRisk Factors
- Prenatal exposure to acetaminophen — especially second and third trimester use
- Male sex (ASD diagnosed 4x more often in males than females)
- Advanced parental age at conception
- Family history of ASD or other neurodevelopmental conditions
- Premature birth or low birth weight
- Prenatal exposure to other endocrine-disrupting chemicals
Treatment Options
Attention Deficit Hyperactivity Disorder (ADHD)
Medical Definition
ADHD is a neurodevelopmental disorder characterized by a persistent pattern of inattention, hyperactivity, and impulsivity that interferes with functioning and development. The DSM-5 recognizes three presentations: predominantly inattentive (formerly ADD), predominantly hyperactive-impulsive, and combined presentation. ADHD is diagnosed in approximately 9.4% of U.S. children aged 2–17, making it one of the most common childhood neurodevelopmental conditions. ADHD-only claimants — that is, children diagnosed with ADHD without comorbid ASD — represent a distinct and underserved group in the acetaminophen litigation. Many ADHD families do not realize they qualify. The JAMA Psychiatry 2020 cord blood study found children with the highest prenatal acetaminophen exposure had a 2.86x increased risk of ADHD — a statistically striking finding. Acetaminophen's disruption of the endocannabinoid system and its effect on prostaglandin synthesis during critical windows of fetal dopaminergic system development are proposed biological mechanisms. Economically, ADHD carries significant and quantifiable lifetime costs: a peer-reviewed economic study found a $1.27 million lifetime earnings gap for individuals with ADHD compared to neurotypical peers, plus substantial costs for behavioral intervention, medication, educational supports, and accident-related harms.
Symptoms
Difficulty sustaining attention on tasks or play activities
CommonFrequent careless mistakes in schoolwork or other activities
CommonDoes not seem to listen when spoken to directly
CommonDifficulty organizing tasks and activities
ModerateExcessive fidgeting, squirming, or leaving seat inappropriately
CommonImpulsive decision-making; difficulty waiting for turns
ModerateEmotional dysregulation, frustration intolerance, mood lability
ModerateAcademic underperformance and social conflict
Warning signRisk Factors
- Prenatal exposure to acetaminophen — JAMA Psychiatry 2020 study found 2.86x increased ADHD risk at highest cord-blood APAP concentrations
- Male sex (diagnosed 2–3x more often in males, though female prevalence is increasingly recognized)
- Family history of ADHD (heritability estimated at 70–80%)
- Prenatal tobacco or alcohol exposure
- Premature birth and low birth weight
- Prenatal stress and maternal immune activation
Treatment Options
Combined ASD and ADHD
Medical Definition
Prior to DSM-5 (2013), clinicians could not diagnose ADHD and autism simultaneously. DSM-5 removed that restriction, recognizing that ASD and ADHD co-occur in a large proportion of cases — studies estimate that 30–80% of individuals with ASD also meet criteria for ADHD, and 20–50% of those with ADHD show features consistent with ASD. The combined ASD+ADHD presentation typically involves greater functional impairment than either diagnosis alone: executive dysfunction compounds social communication difficulties, sensory sensitivities interact with attention and self-regulation challenges, and behavioral escalation events are more frequent. In the acetaminophen litigation, children with combined ASD+ADHD diagnoses represent the highest-severity claimant profile, with compounded lifetime care costs, educational costs, and lost earning capacity. The 2020 JAMA Psychiatry cord blood study found that the highest-exposure children showed elevated risks of both ASD and ADHD, consistent with a dose-response relationship that is legally significant for plaintiffs establishing specific causation.
Symptoms
Combined inattention, hyperactivity, and social communication deficits
SevereSignificantly elevated sensory sensitivities interacting with impulse control
SevereBehavioral escalation events (meltdowns) triggered by sensory or social overload combined with poor self-regulation
SevereMajor academic placement challenges — often requiring specialized therapeutic educational settings
Warning signComplex medication management — stimulants used for ADHD may exacerbate ASD-associated anxiety or stereotyped behaviors
Warning signExecutive function deficits compounding rigid ASD thinking patterns
SevereRisk Factors
- Prenatal acetaminophen exposure — especially high-dose or prolonged second/third trimester use
- Male sex
- Family history of either ASD or ADHD
- Prenatal stress, immune activation, or endocrine disruption
- Prematurity and low birth weight
- Environmental endocrine disruptors in combination with acetaminophen exposure
Treatment Options
Your Legal Team
Sofia Reyes-Montoya
Senior Partner
Los Angeles, CA
Sofia Reyes-Montoya has spent 19 years representing families affected by prenatal pharmaceutical exposure, with a particular focus on neurodevelopmental injury claims. Her neuroscience undergraduate background gives her a foundational understanding of fetal brain development, endocrine disruption, and the biological mechanisms through which prenatal acetaminophen may affect the developing nervous system — expertise she applies directly in working with expert witnesses and educating judges and juries. Sofia has been at the forefront of California's acetaminophen-autism litigation since 2022, successfully defending plaintiffs' expert admissibility under California's Kelly-Frye standard in Alameda County proceedings. She represents families with children diagnosed with both ASD and ADHD and understands the distinct damages profiles for each diagnosis. Sofia has recovered over $60 million for pharmaceutical injury clients and speaks regularly at plaintiff's bar conferences on mass tort strategy for prenatal drug claims.
Education
- J.D., UCLA School of Law (2007)
- B.S., Neuroscience, UC Santa Barbara (2004)
Rachel Okonkwo
Partner
New York, NY
Rachel Okonkwo practices at the intersection of pharmaceutical science and complex federal litigation, with 17 years of experience in pharmaceutical mass tort proceedings in the Southern District of New York and Second Circuit. She has closely followed MDL-3043 since its formation and attended the November 17, 2025 Second Circuit oral arguments in person. Rachel's background in biochemistry and molecular biophysics allows her to engage directly with the scientific literature on prenatal acetaminophen exposure, endocrine disruption, and neurodevelopmental risk — and to identify the methodological arguments most likely to succeed on appellate review. She represents plaintiffs whose federal MDL claims were dismissed and who are seeking to preserve their rights pending the Second Circuit ruling, as well as New York claimants evaluating state court options. Rachel is frequently consulted by other plaintiff's attorneys on Second Circuit appellate strategy for pharmaceutical mass tort cases.
Education
- J.D., Columbia Law School (2009)
- B.S., Biochemistry and Molecular Biophysics, Columbia University (2006)
David Kwon
Partner
Chicago, IL
David Kwon is a Chicago-based mass tort attorney with 15 years of experience litigating product liability and pharmaceutical injury cases in Illinois's most plaintiff-favorable venues — Cook, St. Clair, and Madison counties. His background in psychology informs his work on neurodevelopmental injury claims, including his ability to translate complex ADHD and autism diagnostic criteria into compelling evidence of harm for juries. David has been actively involved in Illinois acetaminophen-autism cases since 2023, working with neuropsychologists, developmental pediatricians, and epidemiologists to build Frye-compliant expert testimony that distinguishes Illinois state proceedings from the federal MDL's Daubert difficulties. He represents both ASD-only and ADHD-only claimants and has particular expertise in evaluating ADHD-only cases, which are often overlooked by mass tort practices focused exclusively on autism diagnoses.
Education
- J.D., Northwestern University Pritzker School of Law (2011)
- B.A., Psychology, University of Chicago (2008)
Frequently Asked Questions
Tylenol Autism and ADHD Lawsuit Filing Deadlines — 2026 Update
The statute of limitations for prenatal acetaminophen–ASD/ADHD claims varies by state but typically runs 2 to 3 years from the date a parent knew or reasonably should have known of the connection between Tylenol use and their child's diagnosis. Because this is an emerging area of law, discovery-rule tolling arguments are more favorable than in established drug litigation. However, statutes of limitations are strict deadlines — waiting is the single greatest risk to a viable claim.
Discovery Rule and Why It Matters for Tylenol-Autism Claimants
In pharmaceutical injury cases involving neurodevelopmental harm to children, courts generally apply the discovery rule — the statute of limitations begins running when a claimant knew or reasonably should have known both of the injury (the child's ASD or ADHD diagnosis) and the connection between that injury and the defendant's conduct (prenatal acetaminophen use and failure to warn). Because the prenatal-acetaminophen-ASD/ADHD link only became widely reported in the mainstream press after the 2021 Nature Reviews Endocrinology consensus statement, many parents had no reasonable basis to connect their child's diagnosis to Tylenol use before 2021 or even 2022. This makes discovery-rule tolling arguments particularly strong for claims filed in 2025 and 2026. Additionally, claims involving minors often benefit from minority tolling — in many states, the statute of limitations does not begin running until the child reaches age 18. An attorney experienced in pharmaceutical mass tort litigation can assess the specific deadline applicable in your state. Critical note: MDL-3043 in the Southern District of New York was dismissed in August 2024 on Daubert grounds — Judge Denise Cote excluded plaintiffs' causation experts. This federal ruling does not affect state court claims in California, Illinois, or other states that apply their own expert admissibility standards. The Second Circuit heard oral arguments on November 17, 2025, with a ruling expected in 2026. Regardless of the appellate outcome, families should consult an attorney promptly to preserve their rights and evaluate state court filing options.
Real-World Examples
A California mother took OTC Tylenol throughout her second trimester in 2016. Her son was diagnosed with autism spectrum disorder (level 2) at age 4 in 2020. She first learned of the Tylenol-autism lawsuit from news coverage of MDL-3043 in late 2022.
California applies a 2-year statute of limitations (CCP § 335.1) with the discovery rule. Under a discovery rule analysis, the limitations period may have begun in late 2022 when she first had reason to connect her prenatal Tylenol use to her son's diagnosis, making her California deadline approximately late 2024 — potentially closed by now. However, California also provides minority tolling: because the child is a minor, the statute may not run until he turns 18 (2034). An attorney must evaluate both theories. Filing now preserves the minority-tolling argument if the 2022 discovery theory has expired. Additionally, California state courts remain active venues for this litigation.
An Illinois mother used generic acetaminophen (CVS brand) during her entire first pregnancy in 2018. Her daughter was diagnosed with ADHD at age 6 in 2024. She is evaluating whether she can file a claim.
Illinois has a 2-year statute of limitations for personal injury with the discovery rule. The ADHD diagnosis occurred in 2024, and widespread media coverage of the acetaminophen-ADHD link followed the 2021 consensus statement and 2022 MDL formation — meaning the limitations period may have begun as early as 2022 or as late as the 2024 diagnosis date, depending on when she reasonably should have made the connection. Illinois state courts (St. Clair, Madison, Cook counties) are active venues for this litigation under the Frye standard. She should consult an attorney immediately.
Bottom Line
Families who used Tylenol or any generic acetaminophen during pregnancy and whose child has been diagnosed with ASD or ADHD should consult a pharmaceutical litigation attorney as soon as possible. Minority tolling may protect claims for children who have not yet turned 18, but do not rely on this without professional evaluation. State courts in California and Illinois remain open. Do not let the federal MDL dismissal deter you from exploring your rights.
In-Depth Guides
Tylenol Liver Damage Lawsuit
Acetaminophen — the active ingredient in Tylenol — is the leading cause of acute liver failure in the United States, responsible for approximately 56,000 emergency room visits, 26,000 hospitalizations, and nearly 500 deaths each year. Lawsuits allege that McNeil Consumer Healthcare and parent company Johnson & Johnson failed to adequately warn consumers about the narrow margin between a therapeutic dose and a potentially fatal overdose. Even doses only slightly above the recommended amount, especially when combined with alcohol use or taken across multiple acetaminophen-containing products, can cause catastrophic liver damage. If you or a loved one suffered acute liver failure, liver transplant, or death linked to acetaminophen use, you may be eligible for compensation. These liver damage claims are separate from the Tylenol autism/ADHD litigation — they involve direct injury to the person who took the medication.
Read guideRead guideRead guideRead guideRead guideRead guideRead guideState-Specific Information
Sources & References
- Prenatal and Postnatal Exposure to Acetaminophen in Relation to Autism Spectrum and Attention-Deficit and Hyperactivity Symptoms in Childhood — Meta-analysis of 130,000+ mother-child pairs — American Journal of Epidemiology, 2018 [Link]
- Association of Acetaminophen Use During Pregnancy With Behavioral Problems in Childhood — JAMA Psychiatry cord blood biomarker study — JAMA Psychiatry, 2020 [Link]
- Consensus Statement: Paracetamol Use During Pregnancy — A Call for Precautionary Action — signed by 91 scientists from 17 countries — Nature Reviews Endocrinology, 2021 [Link]
- Prenatal Acetaminophen Exposure and Risk of Neurodevelopmental Disorders — Mount Sinai study — Multiple outlets, August 2025
- MDL-3043: In re Acetaminophen — ASD/ADHD Products Liability Litigation — Official docket — U.S. District Court, S.D.N.Y. [Link]